A. Al-Homsi

发表

Allogeneic Transplantation to Treat Therapy Related MDS and AML in Adults.

Christopher G. Kanakry, B. Sandmaier, C. Hourigan, 2021, Transplantation and cellular therapy.

Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.

M. Sorror, M. Krem, M. Pasquini, 2021, Transplantation and cellular therapy.

Heparin-induced Thrombocytopenia: Pathophysiology, Diagnosis, and Review of Pharmacotherapy

A. Kanaan, A. Al-Homsi, 2009 .

Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.

R. Vij, D. Lad, M. Perales, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Bone Marrow Cocultured With Human Islets Significantly Improves Islet Survival and Function In Vivo

C. Ricordi, A. Al-Homsi, L. Luo, 2013, Transplantation.

Selective outgrowth of a posttransplant B-immunoblastic lymphoma expressing a latent membrane protein-1 deletion variant.

B. Woda, P. Quesenberry, G. Pihan, 1997, Transplantation.

Calcineurin and mTOR Inhibitor-Free Post-Transplantation Cyclophosphamide and Bortezomib Combination for Graft-versus-Host Disease Prevention after Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I/II Study.

U. Duffner, J. Parker, M. Abidi, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic SCT for adult T-cell leukemia/lymphoma: a review

J. Butera, M. Jabbour, H. Tuncer, 2011, Bone Marrow Transplantation.

Carboxy terminal variants of Epstein-Barr virus-encoded latent membrane protein 1 during long-term human immunodeficiency virus infection: reliable markers for individual strain identification.

M. Kersten, B. Dunn, D. van Baarle, 1999, The Journal of infectious diseases.

Physiochemical, antimicrobial and spectra profile of in-local synthesized Ciprofloxacin Dithiocarbamate

I. A. Hajar, A. Al-Homsi, 2015 .

Human BM stem cells initiate angiogenesis in human islets in vitro

A. Al-Homsi, L. Luo, J. Z. Luo, 2010, Bone Marrow Transplantation.

Current Status and Future Directions in Graft-Versus-Host Disease Prevention Following Allogeneic Blood and Marrow Transplantation in Adults

Cosmin A. Tegla, Frank Cirrone, M. Abdul-Hay, 2020, Clinical hematology international.

Post-transplant cyclophosphamide and bortezomib inhibit dendritic cell maturation and function and alter their IκB and NFκB.

R. Junghans, Z. Lai, A. Al-Homsi, 2014, Transplant immunology.

Human Herpes Virus-6 Encephalitis Following Autologous Blood and Marrow Transplant

Frank Cirrone, M. Abdul-Hay, J. Azzi, 2019, Clinical hematology international.

Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.

M. Bar, J. Wagner, J. Sierra, 2021, Transplantation and cellular therapy.

Phase I Trial of Anti‐PSMA Designer CAR‐T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2‐T Cell Pharmacodynamics as a Determinant of Clinical Response

R. Junghans, A. Bais, E. Gomes, 2016, The Prostate.

Cytokine Modulation of Hematopoietic Stem Cell Phenotype

P. Quesenberry, A. Al-Homsi, 2000 .

Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either Agent Alone.

Yuxin Feng, M. Mclane, A. Al-Homsi, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease.

Yuxin Feng, U. Duffner, A. Al-Homsi, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.

M. Aljurf, R. Gale, J. Pidala, 2020, Journal of Clinical Oncology.

Letter to the Editor Regarding "A Clinical Review of the Different Strategies to Minimize Hemorrhagic Cystitis Associated with the Use of Post-Transplantation Cyclophosphamide in an Allogeneic Transplant".

Frank Cirrone, S. Wo, A. Al-Homsi, 2022, Transplantation and cellular therapy.

Effect of novel proteasome and immunoproteasome inhibitors on dendritic cell maturation, function, and expression of IκB and NFκB.

Z. Lai, A. Al-Homsi, T. Roy, 2013, Transplant immunology.

Bortezomib for the prevention and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Yuxin Feng, U. Duffner, A. Abdel-Mageed, 2016, Experimental hematology.

Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

R. Tibes, Frank Cirrone, M. Grossbard, 2018, Blood.

Initial tacrolimus weight-based dosing strategy in allogeneic hematopoietic stem-cell transplantation

T. Lewis, J. Papadopoulos, Frank Cirrone, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.

P. Hari, R. Gale, Y. Nieto, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation

Frank Cirrone, L. Luznik, M. Abdul-Hay, 2020, Frontiers in Immunology.

Integration of Publicly Reported Center Outcomes into Standards and Accreditation: The FACT Model.

Judy M. Anderson, L. Akard, D. Gastineau, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.

B. Sandmaier, M. Perales, A. Nagler, 2020, Blood advances.

Ixazomib suppresses human dendritic cell and modulates murine graft-versus-host disease in a schedule-dependent fashion.

Yuxin Feng, M. Mclane, A. Al-Homsi, 2017, Experimental hematology.

Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.

U. Duffner, A. Al-Homsi, Kelli A. Cole, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells

P. Quesenberry, A. Al-Homsi, 2020 .

Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.

J. Donovan, A. Kanaan, Matthew A. Silva, 2007, Clinical therapeutics.

Phase I Trial of HuLuc63 in Multiple Myeloma.

N. Munshi, S. Singhal, J. Zonder, 2007 .

Ixazomib Impairs Dendritic Cell Function and T Cell Proliferation and Affects the Development of GvHD in a Schedule-Dependent Fashion

Yuxin Feng, A. Al-Homsi, A. Shen, 2015 .

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

G. Morgan, J. Brayer, C. Lonez, 2021, Blood.

Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

G. Morgan, L. Twyffels, J. Brayer, 2020 .

PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation

J. Goldberg, Frank Cirrone, B. Bruno, 2023, Blood advances.